🇺🇸 erythropoeitin in United States

23 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 4 reports (17.39%)
  2. Blood Creatinine Increased — 3 reports (13.04%)
  3. Acute Respiratory Distress Syndrome — 2 reports (8.7%)
  4. Arrhythmia — 2 reports (8.7%)
  5. Blood Pressure Decreased — 2 reports (8.7%)
  6. Blood Urea Increased — 2 reports (8.7%)
  7. Cerebrovascular Accident — 2 reports (8.7%)
  8. Condition Aggravated — 2 reports (8.7%)
  9. Confusional State — 2 reports (8.7%)
  10. Deep Vein Thrombosis — 2 reports (8.7%)

Source database →

Other Other approved in United States

Frequently asked questions

Is erythropoeitin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for erythropoeitin in United States?

Brigham and Women's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.